GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Piotroski F-Score

Zealand Pharma A/S (Zealand Pharma A/S) Piotroski F-Score : 4 (As of May. 01, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zealand Pharma A/S has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Zealand Pharma A/S's Piotroski F-Score or its related term are showing as below:

ZLDPF' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 5
Current: 4

During the past 13 years, the highest Piotroski F-Score of Zealand Pharma A/S was 5. The lowest was 1. And the median was 3.


Zealand Pharma A/S Piotroski F-Score Historical Data

The historical data trend for Zealand Pharma A/S's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Piotroski F-Score Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 3.00 1.00 4.00 4.00

Zealand Pharma A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 4.00 4.00 4.00

Competitive Comparison of Zealand Pharma A/S's Piotroski F-Score

For the Biotechnology subindustry, Zealand Pharma A/S's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -27.852 + -46.494 + 10.611 + -38.736 = $-102.47 Mil.
Cash Flow from Operations was -28.29 + -25.583 + -16.129 + 8.708 = $-61.29 Mil.
Revenue was 1.96 + 1.514 + 42.291 + 3.4 = $49.17 Mil.
Gross Profit was 1.96 + 1.514 + 41.552 + 1.349 = $46.38 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(219.255 + 192.818 + 298.269 + 311.333 + 289.693) / 5 = $262.2736 Mil.
Total Assets at the begining of this year (Dec22) was $219.26 Mil.
Long-Term Debt & Capital Lease Obligation was $15.01 Mil.
Total Current Assets was $260.40 Mil.
Total Current Liabilities was $41.64 Mil.
Net Income was -33.002 + -69.383 + -19.734 + -48.762 = $-170.88 Mil.

Revenue was 1.623 + 3.606 + 5.815 + 3.407 = $14.45 Mil.
Gross Profit was 1.802 + 3.697 + 5.815 + 3.407 = $14.72 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(314.182 + 272.104 + 178.473 + 145.219 + 219.255) / 5 = $225.8466 Mil.
Total Assets at the begining of last year (Dec21) was $314.18 Mil.
Long-Term Debt & Capital Lease Obligation was $61.05 Mil.
Total Current Assets was $187.44 Mil.
Total Current Liabilities was $27.84 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zealand Pharma A/S's current Net Income (TTM) was -102.47. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zealand Pharma A/S's current Cash Flow from Operations (TTM) was -61.29. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-102.471/219.255
=-0.46735992

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-170.881/314.182
=-0.54389176

Zealand Pharma A/S's return on assets of this year was -0.46735992. Zealand Pharma A/S's return on assets of last year was -0.54389176. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Zealand Pharma A/S's current Net Income (TTM) was -102.47. Zealand Pharma A/S's current Cash Flow from Operations (TTM) was -61.29. ==> -61.29 > -102.47 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=15.008/262.2736
=0.05722269

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=61.049/225.8466
=0.2703118

Zealand Pharma A/S's gearing of this year was 0.05722269. Zealand Pharma A/S's gearing of last year was 0.2703118. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=260.401/41.637
=6.2540769

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=187.437/27.836
=6.73361834

Zealand Pharma A/S's current ratio of this year was 6.2540769. Zealand Pharma A/S's current ratio of last year was 6.73361834. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Zealand Pharma A/S's number of shares in issue this year was 58.374. Zealand Pharma A/S's number of shares in issue last year was 51.032. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=46.375/49.165
=0.94325231

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=14.721/14.451
=1.01868383

Zealand Pharma A/S's gross margin of this year was 0.94325231. Zealand Pharma A/S's gross margin of last year was 1.01868383. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=49.165/219.255
=0.22423662

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=14.451/314.182
=0.04599563

Zealand Pharma A/S's asset turnover of this year was 0.22423662. Zealand Pharma A/S's asset turnover of last year was 0.04599563. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zealand Pharma A/S has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Zealand Pharma A/S  (OTCPK:ZLDPF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Zealand Pharma A/S Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma A/S (Zealand Pharma A/S) Headlines

From GuruFocus

Zealand Pharma to Participate in Upcoming Investor Conferences

By PurpleRose PurpleRose 07-13-2022